Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.42 |
| ▸ | HCK | P08631 | 2/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21792649 | 1.00 | BTK (0.42) | BTKHCKMAP3K12TBK1ITK | |
| SCHEMBL29261762 | 0.91 | BTK (0.41) | BTKHCKTBK1ITKCNR2 | |
| SCHEMBL21792590 | 0.91 | BTK (0.41) | BTKHCKTBK1ITKCNR2 | |
| SCHEMBL28546348 | 0.89 | MAP3K12 (0.46) | BTKHCKMAP3K12ITKCNR2 | |
| SCHEMBL28554401 | 0.89 | MAP3K12 (0.46) | BTKHCKMAP3K12ITKCNR2 | |
| SCHEMBL21792687 | 0.88 | KDR (0.39) | MAP3K12TBK1ITKKDRIRAK1 | |
| SCHEMBL29261761 | 0.88 | BTK (0.42) | BTKHCKMAP3K12ITKCNR2 | |
| SCHEMBL21792591 | 0.88 | BTK (0.42) | BTKHCKMAP3K12ITKCNR2 | |
| SCHEMBL29412176 | 0.88 | BTK (0.42) | BTKHCKMAP3K12ITKCNR2 | |
| SCHEMBL21777159 | 0.87 | BTK (0.54) | BTKHCKMAP3K12ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643954-A2 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-20230094404-A1 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-03-03 | — | — | US | disclosed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094404-A1 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | HNMT, MAOB, PNMT | BTK 3135/4885HCK 1397/4885MAP3K12 3047/4885 |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | H1-5, H1-2, SSB | BTK 133/4885HCK 3523/4885MAP3K12 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.